BioSpace News Archive

Sandoz, the global leader in generic and biosimilar medicines, announced that the European Commission has granted marketing authorization for Wyost®1 and Jubbonti®2, the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe.

Arbutus Biopharma Corporation announced that two abstracts have been accepted for poster and oral presentations at the European Association for the Study of the Liver Congress 2024 taking place June 5 - 8, 2024 in Milan, Italy.

Swixx BioPharma AG, a global commercial platform dedicated to unlocking access to innovative medicines worldwide, announces its strategic expansion into Latin America with the signature of an agreement to acquire 100% of the equity of Pharma Consulting Group S.A. the holding company of Laboratorios Biopas SA.

Oxford Nanopore Technologies announced the launch of a new Pharmacogenomics Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing target enrichment technology with Oxford Nanopore’s sequencing platform.

Antion Biosciences, a Geneva-based cell and gene therapy company developing “off-the-shelf” cell therapies, announces the development of next generation anti-CD19 chimeric antigen receptor T-cells for B-cell driven autoimmune diseases.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens.

I-Mab, a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

Eupraxia Pharmaceuticals Inc. announced that it will host a virtual key opinion leader event on Wednesday, May 29, 2024, at 10:00 AM ET.

Scholar Rock announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist.

Moderna, Inc. announced that three abstracts on mRNA-4157, an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago, IL.